Bristol-Myers to continue M&A activity, R&D chief says

09/23/2009 | Forbes

Bristol-Myers Squibb will pursue more takeovers after its $2.4 billion acquisition of Medarex, said Elliot Sigal, the company's head of research and development. Bristol-Myers expects about a third of its drug portfolio to come from external sources as it prepares to counteract the effects of the so-called patent cliff.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR